Founder, President & CEO, Abilitech Medical
*Bio Coming Soon*
Vice Chair, Licensing, Mayo Clinic Ventures
Andrew J. Danielsen has been with Mayo Clinic Ventures (MCV) since 2002. He oversees the licensing, technology development, and business development functions of MCV. Collectively, these groups work to identify, develop, and commercialize Mayo Clinic intellectual property. In addition, MCV is also involved in co-managing a $250M venture and growth fund and a $30M seed fund. Mr. Danielsen received a B.S. in biochemistry and molecular biology from the University of Wisconsin-Eau Claire, his M.S. degree in molecular biology from the Mayo Graduate School of Medicine, and is a registered Patent Agent.
Dianna G. El Hioum
Partner, Fox Rothschild
Dianna centers her practice on global patent prosecution, licensing and opinion work. With a background in biotechnology, chemistry and large-scale drug manufacturing, she understands the development of drugs and medical devices, from early stage research and patenting to FDA-approval, production and marketing. In addition to her experience in the chemical and pharmaceutical industries, Dianna handles intellectual property issues in the area of shooting sports.
Partner, iGan Partners
Joel Finlayson is an Equity Partner with iGan Partners and the Managing Partner of iGan Advisory for portfolio companies. He has 20 years of strategy consulting & investing experience in healthcare & technology. Joel is an Associate of the Creative Destruction Lab in Toronto and a Director of the Royal College of Physicians & Surgeons of Canada (International). Before joining iGan, Joel was the Co-Founder & Managing Director of WellNovation a family-office funded healthcare incubator based in Riyadh & Dubai that established businesses in diagnostic imaging, primary care & homecare and medical education & training.
Lisa Wipperman Heine
President & CEO, PreCardia
Lisa Wipperman Heine is currently President & CEO of PreCardia, Inc., an early stage medtech company developing an innovative catheter based intervention for the treatment of acute decompensated heart failure. Prior to PreCardia, Lisa was most recently Chief Operating Officer at Mitralign, Inc., a venture backed company focused on development of transcatheter heart valve technologies. Lisa has also served in multiple leadership roles at Covidien, Inc., including Global Vice President of Medical Affairs for Vascular Therapies. During her tenure at Covidien, she helped drive the strategy in support of a $1.7B business and was also responsible for leading the strategy and operations of Clinical Affairs, Healthcare Economics, Policy and Reimbursement and Medical Education functions. Lisa also currently serves as an independent member of the Board of Directors of Surmodics Inc. (NASDAQ: SRDX) and Natus Medical (NASDAQ: BABY).
Vice President Global Marketing & New Business Development Peripheral Interventions, Boston Scientific Corporation
Catherine (Cat) Jennings is the Global Vice President of Marketing and New Business Development for the Peripheral Interventions Division at Boston Scientific. In this role she leads the global marketing function of this $1B division, including portfolio planning, target acquisition assessments, and global commercialization activities. She has worked on multiple acquisitions, distribution and investment deals, as well as having served as the commercial lead for the Bayer Interventional acquisition. Cat joined Guidant/Boston Scientific in 2004. During her tenure with Boston Scientific, she has held multiple marketing roles in both the Rhythm Management and Peripheral Interventions Divisions, as well as a role managing the Corporate Portfolio Process. Previously, Cat worked at MarketBridge, a consulting firm focused on developing sales & marketing strategies for Fortune 500 clients.
Patrice H. Kloss
Partner, Fox Rothschild
Patrice advises medical technology companies, digital health care companies, other emerging businesses and venture capital investors in a broad range of business and commercial matters, including venture capital financings, private placements, venture debt and credit facilities, mergers and acquisitions and securities compliance. She also delivers sound legal counsel to lenders in commercial loan transactions, including $100 million+ loan facilities, and advises clients on equity financing structures and clinical trial agreements. In addition, she routinely provides guidance to boards of directors on fiduciary duties and corporate governance obligations. Prior to joining Fox Rothschild, Patrice was a partner at Oppenheimer Wolff & Donnelly LLP, where she served as co-chair of the firm’s MedTech Practice Group and a member of the firm’s Policy Committee.
President & CEO, Medical Alley Association
Shaye has served as President & CEO of The Medical Alley Association since May, 2014. During this tenure, the association has undertaken significant transformation to focus on championing and facilitating an environment that enables health technology and care organizations to innovate, succeed, and influence the evolution of healthcare. Under Mr. Mandle’s leadership, the association’s vision is to elevate Minnesota’s Medical Alley as the global epicenter of health innovation and care. Mr. Mandle has more than 20 years of experience in government, the private sector and academia, leading organizations, public affairs and political activities. From 2011-2014, Mr. Mandle served as the association’s EVP & COO and its VP of Government & Affiliate Relations. Prior to joining The Medical Alley Association, Mr. Mandle served as the ED of the FedEx Institute of Technology at the University of Memphis, where he launched and oversaw the University Office of Technology Transfer and led the University’s corporate partnership, entrepreneurship and economic development programming.
Managing Partner, Vensana Capital
Kirk Nielsen is a Managing Partner at Vensana Capital, a venture capital & growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Kirk co-founded Vensana in early 2019 as a Managing Director at Versant, where he led the firm's medtech practice. He joined Versant in 2006 from Medtronic, where he worked in sales & marketing in the company’s Cardiac Rhythm Management division. Previously, he spent time at Fluidigm (a Versant portfolio company) and he also served as a consultant at Bain & Company, where he advised clients in healthcare, private equity, and other industries. Prior to his business career, Kirk was a professional hockey player. At Versant, Kirk led or co-led investments in numerous companies that have successfully exited, including Biotie Therapies, Cameron Health, CardiAQ, Ceterix Orthopedics, Lutonix, NeuWave Medical, Sequent Medical, and Zyga Technology, and he remains active with Inari Medical, Metavention, Monteris Medical, Nuvaira, Respicardia, and Veran Medical.
President & CEO, Admedus
Wayne has held numerous, senior positions in multi-national companies and has lived in seven countries during the past 25 years. Through his career, he has been responsible for building and managing multibillion dollar businesses throughout the world, including mergers, integrations, acquisitions and major restructures as President and CEO. From 2005 to 2013 he held senior positions at Merck KGaA, most recently as President of Europe, Canada and Australia. Prior to this, he was President of Emerging Markets, President of Japan and Global Head of Cardiovascular medicine. Between 1999 and 2005, Wayne served at Roche Pharmaceuticals where he was Head of Pharmaceuticals in Roche’s South Korean operation, following his role as Head of Commercial Operations for Roche China based in Shanghai. From April 2015 until November 2016, Wayne served as a Non-Executive Director of Cepheid (NASDAQ: CHPD), a molecular diagnostics company based in California.
Managing Director, Gopher Angels
*Bio Coming Soon*
Managing Partner, Arboretum Ventures
Tom Shehab is a Managing Partner at Arboretum Ventures, a venture capital firm in Ann Arbor, MI specializing in the healthcare sector. He currently serves as a board director for Aira Tech Corp, Fifth Eye, Lucina Health, and SonarMD and led Arboretum’s investment in nVision Medical, which was acquired by Boston Scientific in 2018. Prior to joining Arboretum, Tom spent 12 years as a physician executive and practicing physician specializing in gastroenterology.
Co-Founder & Sr Vice President Business Development, genae
Aly is a thoroughbred clinical researcher with a distinct focus on medical devices. She started her research career as a Clinical Advisor at the Spectranetics Corporation (now Royal Philips, NYSE: PHG) in 1998. She founded the CRO ‘Talen Clinical Trial Management’ in 2001 which led to genae in 2005. The latter transformed to a recognized global services provider for the medical industries, with offices in the US, Europe, Middle East and Asia Pacific.
President & CEO, Nuvaira
Dennis Wahr, M.D. is the CEO of Nuvaira which is developing a unique minimally invasive bronchoscopic treatment for patients with chronic obstructive lung disease called Targeted Lung Denervation (TLD). Prior to joining Nuvaira, Dr. Wahr co-founded Lutonix in 2007 and served as its President and CEO until CR Bard acquired the company in December 2011. Prior to Lutonix, Dr. Wahr co-founded Velocimed in 2001, and served as its President and CEO until its acquisition by St. Jude Medical in 2005. Dr. Wahr has served on the board of directors of several medical device companies including Accumetrics, IDev, Velocimed, and Lutonix, and he currently serves as chairman of the board for Intact Vascular. Additionally, Dr. Wahr spent two years as a Managing Director with RiverVest Ventures focusing on capital investments in emerging medical technology companies. Dr. Wahr was an active board-certified interventional cardiologist prior to launching his entrepreneurial career in 2001.
VP & General Manager, Stryker
Rob is the Vice President and General Manager for Stryker ENT. Prior to taking global responsibility for the ENT business, Rob led Stryker’s Neurovascular business in Europe as the Managing Director. Before joining Stryker, Rob worked in various leadership roles at Medtronic, TriVascular, and Dow. He has a passion to lead the commercialization of innovative technologies and business models that improve lives. Rob received his MBA from Harvard Business School and his BS in Mechanical Engineering from Brigham Young University.